NCT04330820 2024-02-28
RELAX
Technische Universität Dresden
Phase 1/2 Unknown
Clinical Trials
24 trialsNCT05583175 2023-11-28
Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Unknown
NCT05918198 2023-11-21
Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia
Peking University People's Hospital
Phase 2 Unknown
NCT06087419 2023-11-02
A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2 Unknown
NCT06105658 2023-10-30
Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML
Anhui Provincial Hospital
Phase 2 Unknown
NCT06073730 2023-10-10
Viale-a
The Second Affiliated Hospital of Kunming Medical University
Phase 3 Unknown
NCT04754035 2023-10-03
IMPROVE
IRCCS San Raffaele
Phase 2 Unknown
NCT02471391 2023-08-21
AIM
Peter MacCallum Cancer Centre, Australia
Phase 2 Unknown
NCT03867682 2023-08-04
Venetoclax and Lintuzumab-Ac225 in AML Patients
Actinium Pharmaceuticals
Phase 1/2 Unknown
NCT05949762 2023-07-18
Safety and Efficacy of Venetoclax in Combination With Azacitidine and HA Regimen in the Treatment of AML in the Elderly
The Second Affiliated Hospital of Kunming Medical University
Phase 1/2 Unknown
NCT05863845 2023-05-18
Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL
Ruijin Hospital
Phase NA Unknown
NCT05503355 2023-04-04
A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML
BioSight Ltd.
Phase 1/2 Unknown
NCT05312112 2023-03-02
Real World Outcomes Using Novel Agents for AML in the UK
Guy's and St Thomas' NHS Foundation Trust
Unknown
NCT05654194 2022-12-16
Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML
The First Affiliated Hospital of Soochow University
Phase 3 Unknown
NCT04687761 2022-09-08
Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old
PETHEMA Foundation
Phase 1/2 Unknown
NCT05362942 2022-05-05
Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia
Beijing 302 Hospital
Phase 2 Unknown
NCT05053425 2022-04-26
Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML
LanZhou University
Phase NA Unknown
NCT05262465 2022-03-02
Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAML
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase NA Unknown
NCT04613622 2021-10-28
Pharmacokinetics of Venetoclax in Patients With Acute Myeloid Leukemia
National Taiwan University Hospital
Unknown
NCT04616274 2021-10-28
Pharmacokinetics of Venetoclax in Patients With Chronic Lymphocytic Leukemia
National Taiwan University Hospital
Unknown
NCT04824924 2021-04-01
A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for Newly Diagnosed Elderly AML Patients Unfit for Intensive Chemotherapy
Shanghai Jiao Tong University School of Medicine
Phase 2 Unknown
NCT03662724 2021-02-16
VENreg
Hannover Medical School
Unknown
NCT04454580 2020-09-16
Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy
Ospedale Maggiore Di Trieste
Unknown
NCT01211457 2019-07-16
Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)
Cyclacel Pharmaceuticals, Inc.
Phase 1/2 Unknown